Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

CELF2 regulation in multiple myeloma

ABSTRACT: In this study, we analyzed transcriptome sequencing data to compare CELF2 RNA binding protein regulation in multiple myeloma cell line

ORGANISM(S): Homo sapiens

PROVIDER: GSE300088 | GEO | 2025/09/11

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

LINC01432 regulation in multiple myeloma

Project description:In this study, we analyzed transcriptome sequencing data of LINC01432 RNA regulation in a multiple myeloma cell line

2025-09-11 | GSE300566 | GEO

Multiple myeloma

Project description:Multiple myeloma

| PRJNA515992 | ENA

Multiple Myeloma cells

Project description:Multiple Myeloma cells

| PRJNA800411 | ENA

Multiple Myeloma cells

Project description:Multiple Myeloma cell line MM.1S performed ChIP-seq analysis using anti-c-Fos antibody.

2022-01-30 | GSE194381 | GEO

Hypoxia-Induced Regulation of the Proteome in Multiple Myeloma Cell Lines

Project description:Multiple myeloma (MM) is the second most common hematologic malignancy, which is characterized by clonal proliferation of neoplastic plasma cells in the bone marrow. This microenvironment is characterized by low oxygen levels (1-6% O2), known as hypoxia. For MM cells, hypoxia is a physiologic feature that has been described to promote an aggressive phenotype and to confer drug resistance. However, studies on hypoxia are scarce and show little conformity. Here, we analyzed the global proteome in MM cells and the stromal cell line HS-5 to reveal hypoxia-dependent regulation of proteins.

2022-02-16 | PXD030239 | Pride

CD229 promotes multiple myeloma cell proliferation by regulating RAS/ERK pathway

Project description:Flag antibody was used for immunoprecipitation, and cd229-OE partial binding protein was searched by protein spectrum in CD229-OE multiple myeloma cell line, and its interaction was analyzed.

2022-03-09 | PXD032177 |

Serum protein N-glycosylation changes in multiple myeloma

Project description:<h4><strong>BACKGROUND:</strong> Multiple myeloma is characterized by clonal proliferation of malignant plasma cells in the bone marrow that produce monoclonal immunoglobulins. N-glycosylation changes of these monoclonal immunoglobulins have been reported in multiple myeloma, but previous studies only detected limited serum N-glycan features.</h4><h4><strong>METHODS:</strong> Here, a more detailed study of the human serum N-glycome of 91 multiple myeloma patients and 51 controls was performed. We additionally analyzed sequential samples from patients (n = 7) which were obtained at different time points during disease development as well as 16 paired blood serum and bone marrow plasma samples. N-glycans were enzymatically released and measured by mass spectrometry after linkage specific derivatization of sialic acids.</h4><h4><strong>RESULTS:</strong> A decrease in both α2,3- and α2,6-sialylation, galactosylation and an increase in fucosylation within complex-type N-glycans were found in multiple myeloma patients compared to controls, as well as a decrease in difucosylation of diantennary glycans. The observed glycosylation changes were present in all ISS stages, including the 'low-risk' ISS I. In individual patients, difucosylation of diantennary glycans decreased with development of the disease. Protein N-glycosylation features from blood and bone marrow showed strong correlation. Moreover, associations of monoclonal immunoglobulin (M-protein) and albumin levels with glycan traits were discovered in multiple myeloma patients.</h4><h4><strong>CONCLUSIONS & GENERAL SIGNIFICANCE: </strong>In conclusion, serum protein N-glycosylation analysis could successfully distinguish multiple myeloma from healthy controls. Further studies are needed to assess the potential roles of glycan trait changes and the associations of glycans with clinical parameters in multiple myeloma early detection and prognosis.</h4>

2022-04-27 | MTBLS676 | MetaboLights

Regulation of gene expression by HIF-2alpha in multiple myeloma

Project description:Proliferation of neoplastic plasma cells within the bone marrow leads to reduced oxygen availability. In response to hypoxia, the transcription factor hypoxia-inducible factor-2alpha (HIF-2α) is activated and stabilised. We hypothesise that activation of HIF-2α is a central driver of multiple myeloma disease progression, leading to the induction of transcription of genes associated with angiogenesis, osteoclast activation and cell migration. In this study we assessed the affects of HIF-2α overexpression on gene expression in the human myeloma cell line LP-1.

2017-08-04 | GSE102235 | GEO

Transcriptome-wide identification of CELF2 functional targets in T cells

Project description:CELF2 is a critical regulator of alternative splicing during T cell development and during stimulation-induced T cell activation. Here we utilize RNA-seq to globally profile the functional targets of CELF2 in a monoclonal Jurkat T cell line (JSL1 cells), including transcriptome-wide splicing targets and genes regulated at other levels of mRNA processing

2017-04-13 | GSE93594 | GEO

Regulation miRNAs in multiple myeloma

Project description:Regulation of miRNA expression by alpha4beta1 integrin-dependent multiple myeloma cell adhesion

| PRJEB61947 | ENA